Guardant Health Launches First ESG Report
Guardant Health, Inc., a leading precision oncology company, announced the release of its first-ever Environmental, Social & Governance (ESG) Report. This report outlines the company's ESG commitments as part of its overall business strategy.
According to Helmy Eltoukhy, co-founder and co-CEO of Guardant Health, the company's primary objective is to provide cancer tests that enable patients to lead longer and healthier lives. He emphasises the importance of responsible actions towards employees, communities, and the environment. The inaugural report showcases current ESG initiatives and recent accomplishments, such as promoting diversity and inclusion within the workforce and clinical trials.
Key highlights from Guardant Health's 2023 ESG Report include:
Entrusting the Nominating and Corporate Governance Committee of the company's Board of Directors with oversight responsibilities for ESG matters.
Nurturing a diverse and inclusive workforce, with women representing approximately 56% and non-White employees accounting for 60% as of December 31, 2022.
Recognising the company's role in promoting diversity by enrolling diverse patient populations in clinical trials and collaborating with local communities to enhance diverse enrollment.
Implementing processes to measure vital sustainability-related data across Guardant Health's global operations.
AmirAli Talasaz, co-founder and co-CEO of Guardant Health reaffirms the company's commitment to integrating ESG considerations into its business strategy, aligning with its mission to improve human health. He expresses enthusiasm for the ongoing execution of ESG initiatives and promises further updates on their progress.
To access Guardant Health's 2023 ESG Report, visit: http://investors.guardanthealth.com/corporate-governance/esg.
To view and compare company ESG Ratings and Sustainability Reports across sectors, follow our Company ESG Profiles page.
Source: Business Wire